PsiThera integrates biophysics, advanced computational modeling, and mechanistic biology to identify biologically relevant protein states and design optimized oral therapeutics targeting immune and inflammatory conditions. The company’s platform is intended to uncover novel therapeutic opportunities that traditional discovery approaches overlook. By focusing on protein conformations, PsiThera aims to create drugs with improved selectivity and efficacy. The organization is led by CEO Eric Shaff alongside Woody Sherman, Ph.D. (Chief Innovation Officer), Camil Sayegh, Ph.D. (Chief Scientific Officer), Jean-Christophe Harmange, Pharm.D., Ph.D. (SVP, Drug Discovery), and Kal Lapan, Ph.D. (VP, Head of Operations). The business plans to channel new capital into expanding its operations and advancing drug-development programs. PsiThera’s most recent financing—its $47.5 million Series A—provides the company’s current financial footing and resources for further growth.

Total raised

$48M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025